The future of oncology: A focused approach to winning in 2030
The future of oncology
An analysis of how current business models can be adapted to mitigate the effects of a changing oncology paradigm
Oncology treatments used to promise some of the highest returns for pharmaceutical manufacturers. However, R&D costs, shorter product life cycles, fragmented patient markets and pressure on healthcare budgets are changing the industry’s status quo.
The age of the ‘one-size-fits-all’ oncology therapy is ending, and with it the blockbuster model that has for so long driven shareholder value. The future of oncology: A focused approach to winning in 2030 analyses how current business models can be adapted to mitigate the effects of a changing oncology paradigm.
© 2022 KPMG Huazhen LLP, a People's Republic of China partnership, KPMG Advisory (China) Limited, a limited liability company in Mainland China, KPMG, a Macau (SAR) partnership, and KPMG, a Hong Kong (SAR) partnership, are member firms of the KPMG global organisation of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.
The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organisation.
For more detail about the structure of the KPMG global organisation please visit https://home.kpmg/governance.